ISSN No:-2456-2165

A Systemic Summary of Nanotechnology's Current and Prospective Scope in Drugs Delivery

Aditi Chaudhary[1*], Ravi kumar [2], Ajit Kumar Varma[3]
[1]Faculty of Pharmaceutical Sciences, Rama University, Mandhana, Kanpur (U.P.) India-209217

Corresponding Author:- Aditi Chaudhary[1*]

Abstract:- The creation of drug formulations based on nanoparticles offers the possibility to tackle and treat challenging diseases. The size of nanoparticles varies between 100 and 500 nm. By changing their size, surface characteristics, and structure, nanoparticles can be transformed into intelligent systems. The idea was put forth as a workable substitute with the ability to target and administer drugs. The use of nanobiotechnology in viral, autoimmune, and inflammatory diseases is numerous. Nanoparticles have biomimetic properties like medication formulation and encapsulation. Nanomaterials are substances based on graphene for stem cell and tissue engineering constitute a few of the most contemporary graphene developments.

Keywords:- *Nanotechnology, Future of Nanotechnology, Cancer Stem Cell(CSC), Gold Nanoparticles (AuNPs), Gold Nanorods (AuNRs), Drug Delivery Systems (DDs)*

I. INTRODUCTION

➢ *Nanomedicine in Cancer*

Cancer is one of the leading causes of death, ranking second in developing nations and becoming more prevalent over time [1]. Surgery, radiation, and chemotherapy are currently used in cancer treatment, with cancer treatment being the most successful, particularly in advanced stages. Cancer is one of the leading causes of death in the globe, ranking second in developing nations and increasing in prevalence over time[1]. Currently, cancer is treated with surgery, radiation, and chemotherapy, with chemotherapy being the most effective, especially in advanced stages. [2,3]. Despite this strong reaction, anticancer drugs are given in higher doses to achieve a final tolerable concentration in the target tissues or organs, and this practice is repeated with each chemotherapy cycle. [4] Even though the introduction of new agents into cancer therapy has significantly improved patient survival, there are still several biological barriers that impede drug delivery to target cells and tissues, such as unpleasant blood half-life, physiologic behavior with significant off-target effects, and effective clearance from the human organism. [5,6]. Cancer stem cells (CSC) are a subpopulation of cancerous cells that, like normal stem cells, may conscience, give birth to a large variety of daughter cells, and proliferate rapidly. [7,8]. Although traditional chemotherapeutic targets rapidly proliferating cells, which represent the majority of non-stem cells in a tumor, CSC are frequently vulnerable to those agents. [9]. Side effects in healthy cells (e.g., nephrotoxicity, neurotoxicity, cardiotoxicity, and so on) and pathogenicity (MDR) methods developed by cancer cells cause a decrease in the concentration of the drug at the targeted site, poor accumulation in the tumor, and a corresponding decrease in efficacy, that could be associated with diagnosis treatment failure. [10,11,12,13]. Cancer cell therapies that are less toxic and more sensitive, such as improved pharmaceuticals, substance devices (DDSs), and chromosomal drug carriers, are crucial for addressing these difficulties while boosting the efficacy of chemotherapeutic therapies. [14].

Fig 1 Showing Various Types of Nanocarriers used as Nanomedicine for Treatment of Cancer.

ISSN No:-2456-2165

Nanotechnology is defined as the manipulation of material on an atomic, molecular, and organometallic chemistry scale, in addition to the design, development, assessment, and deployment of different nanoscale materials in a wide range of important sectors, most notably medical.(So-called Nanomedicine) [15,16]. The rapid recognition of tumour cells and/or tumour tissue characteristics, as well as the improvement of the efficacy of treatment, provide the foundation for nanotechnology drug delivery system investigation and modification [17]. Physiological effects are among the most fundamental nanostructure materials as shown in Figure 2.



Fig 2 Biomedical Application of Nanotherapeutics

The performance of these nanotherapeutics in oncology is predicated on passive targeting produced by antigenic vasculature with adequate circulation and anomalous lymphatic flow surrounding the tumour. [18], which can be strengthened further by ii) personalized marketing based on homogeneous nanotechnology that can penetrate the epithelium and reach cancerous cells. [19]. Nanotechnology allows novel and more effective pharmaceutical delivery and administration procedures, decreasing toxicity and other negative environmental consequences while maintaining or increasing the therapeutic index. [20, 21, 22, 23].In essence, the ultimate goal of cancer therapy is the development of personalized delivery systems, which has resulted in the abolition of the MDR problem. [24, 25]. e will go over some of the most prevalent applications of platforms, focusing on Methods for targeted gene silencing, as well as the best approaches for testing these therapeutics in vitro and in vivo. A consideration of the dangerous features of such medications will also be provided.

➢ *Nanoparticles as Drug Carriers*

Nanoparticles have been discovered as effective cancer therapy target-specific methods, acting as solid lipid nanoparticles as well as therapy materials [26]. Over the last few decades, several varieties of nanoparticles have been generated, utilizing a comprehensive variety of substances such as carbon, silica oxides, metal oxides, nanostructures, lipids, polysaccharides, nanostructured materials, and polymeric nanoparticles, as well as the recent phenomenon of template for the synthesis compounds. [27]. Nanoparticles have been discovered as effective cancer therapy target-specific methods, acting as solid lipid nanoparticles as well as therapy materials [28]. Over the last few decades, several varieties of nanoparticles have been generated, utilizing a comprehensive variety of substances such as carbon, silica oxides, metal oxides, nanostructures, lipids, polysaccharides, nanostructures materials, and polymeric nanoparticles, as well as a recent phenomenon of template for the synthesis compounds. [29].

Furthermore, preservation from plasma protein adherence and/or removal by circulating nucleases improves cytokine and chemokine bioavailability at the site of focus. This is supported further by the substantial reduction in removal from the organism achieved by nanoparticle encapsulation. When trying to transform the mode of management (and associated vehicle and route of administration), the evolution of pharmacokinetic and pharmacokinetic parameters is an essential aspect that is largely overlooked when compared to the potential of pharmacotherapy nanoconjugates to available to overcome targeting (active and/or passive) and epithelial uptake. When exploring nanoparticles for medical strategies, it is important to assess the influence on mitochondrial function and death that can be realized through suitable coupling with (bio) molecules of relevance.DDSs can enhance the properties of free medicines by enhancing overall in vitro evaluation and pharmacokinetic profile, stability, and even pharmacokinetic management, hence promoting drug transport and, more significantly, drug release in the target region. [30].

Drug delivery systems can be created utilizing direct drug crosslinking, and surface properties can improve delivery by improving tailored movement to specific cell

types and targeting cell divisions such as the mitochondria and the nucleus [31]. Solid lipid nanoparticles, polymer prodrugs, nanocrystals (such as AuNPs), nanocapsules, microparticles, nanoshells, and polyamide and nucleic acid-based nanoparticles are the most significant nanoparticle vehicles for drug delivery. [32]

Nanoparticle size, connectivity orientation, and the presence of a range of different ligands on their surfaces may all increase their use in cancer treatment [33]. The high surface characteristics and other critical characteristics of nanoparticles can be changed to just provide solutions suitable for either qualitative or quantitative analysis methodologies of primary cancer cells. Nanoparticle size, connectivity form, and the occurrence of a wide range of different ligands on their surfaces may all increase their use in anticancer therapy [34]. The high surface features and other critical characteristics of nanomaterials can be changed and can provide demonstrate the applicability of either qualitative or quantitative approaches to growing cancer cells. [35]

Cancer cells are addressed alternatively passively and aggressively. [36]. Supplementary targeting of cancerous cells by nanotechnology is depending on EPR changes caused by angiogenic endothelium with sufficient perfusion and capillary flow, which generates a larger amount in cancerous cells than in normal cells. [37]. When compared with conventional therapy, nanoparticles can reduce tumor size by more than threefold. [38].

The proportion of particles in the circulatory system, their size and membrane characteristics, and, in some circumstances, the level of hypoxia all affect whether they are disseminated. [39,40,41,42]. Despite the improved permeability within the malignancy, this approach causes serious questions about the efficiency of such an approach, which is premised on a wrong assumption. [43,44]. The destinations are chosen based on their concentrations on the cellular membrane, quantitative procedures, and the ability of the substances as a compound to absorb. [45,46,47, 48]. Despite the absence of any strong correlation between both therapeutic effects and the overall amount of nanostructures gathered within the malignancy, it is thought to change nanoparticle permeability via receptor-mediated successful integration and enhance the effectiveness of anti-tumor prescription drugs with receptor molecules. [48,49,50].

Active targeting is a potential mechanism for microparticles to deliver chemotherapy drugs to cancer cells and, as a result, is currently one of the primary vectors of DDS progress at the moment, trying to incorporate nanomaterial tailoring to produce significant and efficient cargo without having to compromise controlled delivery. gold nanoparticles (AuNPs).[51]

Metallic nanostructures are more adaptable than other nanomaterials because they can modify size, shape, shape, structure, assembly, and encapsulated, and tunable optical characteristics [52]. Among some of the metallic nanomaterials for application, AuNPs have caught the medical group's interest due to their outstanding efficacy in cancer therapy [53,54]. The fascination with AuNPs stems from their tunable refractive index, which can be changed and modified for therapeutic strategies and diagnostics. [55,56].

II. MANUFACTURING, SYNTHESIS METHOD, IDENTIFICATION, AND PROPERTIES OF AuNPs

The formation of nanoparticles is associated with a plethora of properties that are dependent on the substances' great consistency in physicochemical parameters, which greatly impact the size, size, and area.[57]

The primary method for making nanoparticles comprises the chemical introduction of synthesized compounds that stick toward the interfaces of nanotechnology ([58] and references therein). AuNPs of various shapes and sizes can be created by decreasing gold with a diverse range of agents, comprising the main advantages of this method are a disulfide group, a heterocyclic chain, and a charged end arrangement, which reduces agglomeration of nanoparticles. [59]. Furthermore, this deep learning model of a binding material promotes a full change in the surface properties of AuNPs, allowing binding agreement with a wide range of molecules, boosting AuNPs techniques to solve, and ultimately improving particle stability in physiologic situations [60, 61]. Once AuNPs have already been implicated in chemical and non-covalent interaction, treatments exploiting their capability to transport diverse functional groups can be designed. (Figure3)[62,63,64]



Fig 3 Cancer Targeting, Delivery, and Imaging Systems Based on Nanoparticles (Nps).

These novel NPs are composed of a specified moiety; Nanoparticles carrying an inhibiting component as well as chemotherapeutic treatment are administered to the appropriate tissue. Depending on the particular system, they may be reachable on the subsurface or within the NPs. Monitoring compounds that have been connected to the surface of the particle's surface and utilized as monitoring and/or contrast agents can be administered using heterogeneous data. A large fraction of targeted delivery AuNPs has a PEG-coated surface for biocompatibility and "stealth" [58]. It should be highlighted that enhanced hydrophilicity on the surface of AuNPs can diminish their uptake by cancer cells, hindering effective medicine delivery to tumors via passive targeting nanoparticles. [65]

Another of the most crucial components of the targeting methodology is the selection of appropriate targeting ligands, maybe by optimizing their oxidation and reduction following the antibiotic toxicity surface of AuNPs. More particular, two critical ligand characteristics, affinities, and concentration can play a key role in proper nanoparticle distribution to the cell's extracellular environment.[66]

Again, ligand covalently conjugated is restricted by the combination of morphological advantages (for ligand-receptor connection) and infinite complicated drawbacks (stretching, flexibility, or compressibility of the nanosystem). As an example. [67].

UV-Vis spectroscopy is used to evaluate the surface plasmon resonance (SPR) of accent pillows, TEM is used to assess the overall dimension of the particles, SEM is used to illustrate the thermodynamic qualities, and Spectroscopy Measurement can be employed to measure the amount of gold [68]. The drug concentration of AuNPs can be assessed in advance of the release of their carrier, allowing for the creation of a therapeutic intervention. [69].

AuNPs are appropriate for in vitro diagnosis, in vivo evaluation, regenerative medicine, and as DDSs because of their outstanding biocompatibility, high water attempting to resolve the matter, adequate morphologies and constrained dispersibility, low particular surface area ratio, non-toxicity in cellular signaling pathways, and simplicity of synthesis and biocompatibility and biodegradability with a diverse collection of biological macromolecules (targeting and silencing functionalization). [70-75].

III. AuNPs IN CANCER THERAPY

➢ *AuNPs in Photothermal Therapy*

Because of their properties that are particularly necessary because of the numerous disease specificities, AuNP preparations have a considerable influence on chemotherapeutic therapies in complex settings. AuNPs have changing optical properties, which allow them to penetrate from near UV to near UV, AuNPs formulations have a massive impact on chemotherapeutic regimens in getting more and more involved due to their characteristics, which are extremely crucial because of the different disease-specific characteristics. AuNPs have variable optical characteristics that enable them to permeate from near UV to near UV, allowing nanotechnology to penetrate cells, which is a massive step forward in their usage in photothermal radiation chemotherapy or environmental control. Imitating nanoparticles to infiltrate cells, which is a big step further in their use in photothermal therapy chemotherapeutic or temperature [76]. This is said when growing surface temperatures above 42oC result in a decrease in cell viability. [77]



Fig 4 Diagram Showing the Effects of Photothermal Therapy (PTT) and Photodynamic Therapy (PDT) Utilising Gold Nanoparticles on the Body's Physiology and Biology. Many Gold Nanoparticles Accumulate as a Result of the Tumor's Leaky Vasculature. In Response to Near-Infrared Light and Reactive Oxidants (ROS) Created by Secondarily Administered Photosensitizers (PS), this Results in a Photo-Thermal Impact that Ultimately Leads Cancer Tissue to Experience Apoptosis and Necrosis.Higher Cellular Absorption and Transfection Efficiency, as well as Increased Lipid DNA Complex Stability

➢ *AuNPs as Drug Delivery Systems*

The previously mentioned well-known implementation of AuNPs in chemotherapeutic agents sparked extensive research into future potential therapeutic approaches and demonstrated that AuNPs can be used in the manufacturing of drug carriers [78]. The appeal of using AuNPs as drug discovery platforms arises from their simplicity of synthesis and cross-linking. According to investigations, connecting with some of these payloads has a substantial ability to eradicate malignant cells [79]. As explained previously, AuNPs can transport a wide range of payloads, including tiny drug molecules for drug delivery and biomaterials such as DNA, enzymes, and RNA (siRNAs), which have been recognized as interesting gene distribution methods.[80]

- *Mode of Delivery*

The direct binds of two types of pharmacotherapy operational processes in nanostructures, namely a tyrosine kinase inhibitor and a specific cancer cell intended biotransformation, work together as a single system in a synergetic way to encourage greater precision to cancerous cells to demonstrate them to the economically efficient methodology of anticancer agent release, circumventing genetic and various physicochemical barriers. [81,82]



Fig 5 The Gold Nanoparticle is Depicted Schematically, Along with Some of its Potential Applications in Biomedicine. Based on its Intended Purpose, the Gold Nanoparticle May Be Marked with One or More Substances, such as Tags for Medications or Tags for the Transport of Nucleotides or Protein Fragments. By Utilising Antibody-Tagged Gnps or Ligands Attached to them that Target Particular Body Receptors, its Contents can be Directed to the Right Cells in the Body. The Introduction of GNP-Tagged Dye Optical Probe has Greatly Advanced Imaging Capabilities.

➢ *AuNPs in Specific Targeting*

To address these difficulties, the vaccine must be administered in a tailored manner [83]. A matrix into the intermembranous region for drug administration can comprise several anti-cancer chemicals that will be supplied to cancer cells and have therapeutic value. It is possible to enhance therapeutic efficacy while minimizing permeation and off-target consequences, as well as using tumour molecular biology approaches as points of attachment to consolidate the physiological effect of cancer. Several of these dangerous genetic approaches include surface pharmacological responses visible in tumour tissues in the vascular regions that are destroyed or produced at significantly lower rates in normal cells, allowing tumour bulk to be differentiated from neighbouring normal tissues [84-85]. Based on planned and controlled workflows and processes [86].

This technique could be a viable cancer therapy tool if it can reliably discriminate malignant cells from non-cancer cells, which is a big difficulty with existing chemotherapeutic medicines [87,88]. The increase in surface area of AuNPs, together with other attributes such as earlier communication mechanisms and reflection coefficient properties, appears to be required for the development of adequate bio-detection molecules [89]. The potential of AuNPs to integrate diagnostic and therapeutic procedures can be employed to increase the therapeutic capability of such systems. The ranostics can boost medication release at specific malignant cells, targeted molecules, or compounds, and this can be seen throughout the system. [90,91,92].

Polysaccharides such as RGD [93-95], proteins such as coagulation factors, the epidermis growth factor (EGF), and polysaccharide [96] molecules such as solid lipid nanoparticles [97], and biologics [98] are examples of malignant cells macromolecules. Anti-epithelial growth receptor (EGFR) new therapies have been used as an active implementation of the methodology since EGFR and its ligands are widely abundantly expressed in a wide range of solid tumours. [99-100].

Cross linking of AuNPs with appropriate ssDNA particles (Au-nanoprobes) is a promising detection technique for such Genomic substrates since it is fast, sensitive, selective, and inexpensive [101]. For example, a cancerous cell's constitutively active folate receptor can be selectively targeted by AuNPs polymerized with folate receptors, and then the therapeutic Doxorubicin (DOX) can be introduced into them and cause excessive toxicity than the one utilized earlier. When compared to DOX alone in healthy tissue (which does not produce these ligands) [102-105]. The CSC pool's cell-surface unique markers, on the other hand, provide a way for identifying those cells throughout the tumor [106]. Treatment approaches must focus on this specific CSC niche rather than the quickly divided to avoid inhibition of growth.

ISSN No:-2456-2165

Addressing cancer angiogenesis capillaries is also receiving greater attention due to its potential to increase treatment efficacy in cases where malignant cells are challenging to reach [107-109]. Advertising, either alone or in combination with targeted delivery technologies, may aid in the endocytic of AuNP pharmaceutical candidates in certain receptors [110-115]. Tissue patterns, which are manufactured sequences that aid in the distribution of various weights to cells, or nuclear localization sequences, which direct containers to the center, can also be employed to direct the cellular localization of compounds [116-119]. Nanotechnology can impede communication by imbuing AuNPs with proton sponge moieties, such as through photodynamic warming [120]. The therapeutic effects of AuNPs have been shown to boost tumour growth. [121]. (6-13% versus 2-5%) [122].

- *AuNPs for Drug/Cargo Delivery:*

The shape, charge, and surface composition of AuNPs determine their adsorption effectiveness and subcellular destiny [123]. The flexibility to outfit AuNPs with a variety of cargos allows for the development of a diverse variety of drug delivery systems [124-125]. Additionally, when using nanotechnology as DDSs, two crucial characteristics to examine are continuous nano vectorization mechanism in the circulation, bioavailable rate, and carriers clearance. [126-129]. The use of nanotechnology to supply these service systems suggests the ability to penetrate the skin barrier by producing small molecular-weight substances that spread quickly throughout the body, compelling tumour tumours to differentiate [130].

The particular chemical active discharge is controlled by its connections with AuNPs (cross linking or non-covalent adhesion) as well as its mode of releasing within cells [131]. Non-covalent absorption, such as that achieved for hydrophilic medicines, does not affect drug management [132], although covalent connections, such as those produced for prodrugs, necessitate the use of either internal or external processes [133] The absorption bands of AuNPs' edges are significant for dosing regimens that use either internal or exterior stimuli [134-135]. Photo-regulated release, in which light is used to photo-cleave the nanomaterials connection,

AuNP cysteine and cytoplasmic glutamate [136]. Recently, it has been demonstrated that AuNPs coated with doxorubicin could decrease cancer cell susceptibility to treatment. [137-138].

AuNPs with a high degree of specificity have been identified as having the potential to interact with a diverse variety of platinum pharmaceuticals [139-140]. Brown and colleagues conducted a platinum-tethered AuNP system with the pharmacologically important oxaliplatin as its chromium-based moiety and tested it in lung and colon carcinoma cell lines, trying to demonstrate greater cytotoxicity than monotherapy alone as well as increased accumulation of the bioactive components within certain cancer cells, attempting to achieve the nucleus for possible future DNA interaction, resulting in a financially beneficial delivery method. [141-145].

- *AuNPs for Gene Therapy*

Although gene therapy is seen as a promising technique in cancer treatment, with the potential to be as effective as chemotherapy or radiotherapy, its implementation is dependent on bacteriophages, raising concerns regarding neurotoxicity and immune function [146]. Under controlled conditions, siRNAs coupled to AuNPs demonstrated enhanced stability, encapsulation efficiency, and potency while remaining active in RNAi pathways [147]. Rosi and colleagues demonstrated for the first time in 2006 that the DNA-AuNP component could be integrated into cells without the need for replicating agents and repressed genes using a different technique. [148]. Once the genetic material had been maintained from disintegration by DNAse I, AuNPs appeared to be a potential gene delivery technique [149]. Han and colleagues created [150]. Although gene therapy is seen as a promising technique in cancer therapy, with the potential to be as powerful as chemotherapy and radiotherapy, its execution is dependent on bacteriophages, raising concerns regarding neurotoxicity and immune function [156-159]. Under certain conditions, siRNAs coupled to AuNPs demonstrated enhanced stability, encapsulation efficiency, and potency while remaining active in the RNAi pathways [160]. Rosi and colleagues revealed in 2006 for the first time that the DNA-AuNP component could be integrated into cells without the assistance of replicating agents and repressed genes using an alternate technique. [161]. Once the genetic material had been protected from disintegration by DNAse I, AuNPs appeared to be a potential gene delivery strategy [162]. Han and his colleagues invented [163].

Table 1 AuNP Construct for Gene Delivery using Different Stabilizers. The Assembled Platforms Incorporate Genetic Materials Either by Covalent Bonding or by Electrostatic Interaction and Display Unique Characteristic Features, which Enable them as a Potential Carrier for Gene Delivery.

Stabilizers	AuNPs construct	Unique features
siRNA Nucleotides	Nucleotide monolayer nanoparticals	High cellular absorption, low toxicity, low susceptibility to degarbadation by nuclease activity, and high affinity constant for complementary nucleic acid
Polyethyleneimine(PEI)	Cationic polymer monolayer nanoparticals	Increased binding capacity, increased stability in physiologic conditions, increased cellular absorption, and decreased cellular toxicity
Dimethyldioctadecy-1ammonium bromide(DODAB)	Cationic lipid assembled nanoparticles	Higher cellular absorption and transfection efficiency, as well as increased lipid DNA complex stability

This in vivo methodological approach is already widely used, emphasizing the significance of removing the residual obstacles that prevent direct implementation. The most recent research findings are emphasized. Zhang and associates [164] established anti-metastasis marketing pertains to gold nanorods (AuNRs) electrostatic repulsion connected with siRNAs addressing the proteolytic enzymes receptor 1. (PAR-1). These moieties were then delivered to polymorphonuclear inflammatory cells from malignant human breast cancer patients. The researchers discovered that efficient PAR-1 mRNA and transcription reduction, as well as decreased cancer cell propagating potential, were observed [165]. The earlier can be created with a specific reason, such as.

AuNPs appeared to be a promising gene delivery approach once the genetic information had been protected from disintegration by DNAse.This in vivo methodology is now frequently utilized, and the need of overcoming the remaining obstacles that limit its clinical usefulness is acknowledged. The most recent study is underlined. Zhang and associates. created an anti-metastasis method that combines the electrostatic interaction of gold nanorods (AuNRs) with siRNAs addressing the proteolytic protease receptor (PAR-1). These metabolites were then given to polymorphonuclear leukocytes in individuals with advanced breast cancer in humans. The researchers discovered effective PAR-1 mRNA and expression inhibition, as well as a reduced capacity for the proliferation of cancer cells. MiRNAs have also been connected to tumor genesis, progression, and differentiation. MiRNAs can act as genetic alterations or immune cell genetic mutations in cells, according to their expression, which could represent a breakthrough in anticancer therapy. Conde and coworkers reported an Au-nano beacon-based technology for targeting and efficiently inhibiting miR-21, a carcinogenic miRNA that is commonly up-regulated in almost all types of cancers. This approach for targeting cancerous cells can resolve the issue of resistant strains. ATP is connected to one of the main components of resistant organisms in cancer.

ABC integral membrane proteins that can be suppressed for treating cancer include P-glycoprotein (P-gp) and some other efflux proteins such as BCRP. Cancer stem cells (CSCs) can also manufacture these antigens on the surface, which confer resistance to currently established anticancer approaches. As a result, the significance of suppressing these leukemia pathways evolves to decrease cancer susceptibility barriers to genuine chemotherapeutics and then developed an effective response to the therapeutic drugs used. A system of lipid-modified connected nanoparticles encapsulating siRNAs addressing the ABCB1 gene (P-gp) indicates that this technique can rapidly spread the siRNA monomer while also limiting P-gp transcription. When efflux pump-mediated tolerance is missing, another careful preparation mechanism substitutes for it.

- *Toxicity of AuNPs*

The toxicity of AuNPs in biological systems, which induces neurotoxicity in cancerous cells as well as surrounding healthy cells, is a major concern concerning their usage in medicine. Because the size, fabrication method, and accessibility of nano vectorization systems are important for developing biomaterials, they may be safer when deployed in cancer chemotherapy. In actuality, the size of nanoparticles is control of various types since it allows them to avoid the inflammation system and clear promptly, preserving the therapeutic potential of such systems. The cytotoxicity of AuNPs is thought to be influenced by particle size, shape, zeta potential, and biochemistry. As a result, it is expected that smaller AuNPs, comparable to polysaccharides, will be more powerful.

Particles with a size of about 50 nm. Surface modification appears to cause more apoptotic cell death than unmodified 40 nm AuNPs, which is primarily likely due to increased gained significant traction. Prolonged damage is the primary cause of AuNP toxicity, compared to in vitro experiments. Indeed, AuNPs enhanced the transcription of anxiousness genes while decreasing the manufacture of cell process genes [145-147]. The preponderance of these papers, however, concentrated on genomic damage, including such breaks in Genetic material and nuclear irregularities, or on finding proteins toxicity biomarkers. A thorough toxicological evaluation that takes into consideration genetic mutations, stress-related molecules, and a molecular profiling approach.

AuNPs, on the other hand, are generally seen as a system that does not produce acute or ongoing toxicity and therefore is regarded as a safer therapeutic approach. Since of their ease of usage, AuNPs have been demonstrated to be a safe system. This idea is based on the assumption that nanocomposites have no effect on cells and that the functionality moiety on their membrane promotes the desired cytotoxic activity. In comparison, expression studies revealed an increase in the transcription of pressure and inflammatory mediators genes after AuNPs administration, which has been connected to AuNPs' action in the production of oxidative stress. There was also a decrease in the cell cycle expression of genes, indicating irreparable harm that causes the death of cells.

AuNPs, on the other hand, are commonly viewed as a mechanism that doesn't generate acute or long-term toxicity, and hence safer therapeutic options are advocated. AuNPs are a safe system because of their flexibility. This idea is based on the premise that gold nanoparticles have no effect on cells since the function aspect on their surfaces contributes to the targeted cytotoxic effect. On either hand, transcription investigations have demonstrated a boost in the expression of stress and inflammatory cytokines genes following AuNPs delivery, which has been linked to AuNPs' role in the development of oxidative stress. Cell cycle genetic information had also been decreased, demonstrating irreparable damage that causes the death of cells.

The development of AuNPs in mice indicates that the vast majority of systemically delivered nanomaterials, regardless of size, are stored throughout the liver. There is an additional agreement that AuNPs with such a cut-off dimension of nearly 20 nm can penetrate the blood-brain barrier and access the brain, and that tiny compounds have the most extensive organ circulation. A complex link between particle diameter and organ distribution exists. It is known, for example, because kidney elimination of AuNPs is maximized within a restricted size range of 6-8 nm, resulting in a greater conviction rate. Regardless of the importance of animal models, evaluating the effect of size on AuNP cytotoxicity is difficult.

- *AuNPs in Radiotherapy*

AuNPs have been examined in radiation exploration to solve the dangers associated with brachytherapy healthful tissue damage. This technique is based on the well-known accumulation of AuNPs in cancer, which acts as a decoy to concentrate the radiotherapy in the malignant and limit its impact in the normal tumor surrounding, allowing the initial dose of radiation administered to be lowered. A long-term study using AuNPs and radioactive materials in mice with surgically implanted devices in cancerous tissue to avoid the potential of cancer cell causal connection leads to a decrease of lymph node metastasis until it can no longer be recognized and an 86% long-term remedial measures,i.e. for more than a year, which is considerably higher than the 20% survival rate.

- *AuNPs in Angiogenesis Inhibition*

Some other efficient approach for deploying AuNPs in cancer therapy is to prevent ischemia or the development of new blood vessels. AuNPs can prevent the modifications of proteins that are involved in this generation of capillaries by interfering with disulphide compounds in heparin-binding signal transduction pathways. In addition, the AuNPs can be bombarded intravenously, causing vascular permeability and an interruption in the oxygen and nutrient delivery to the tumors. Radiation exposure character traits reduced exercise toward the niche of central cells, which have become self-sufficient in blood supply, cerebral hypoxia, and with the reduction in cell division potential, typically results in continuous preservation and safeguarding of such cells, which is the main cause of cancer cell survival.

- *Graphene Based Delivery-*

Nanotechnology is the creation and application of materials and devices on a molecular and atomic scale that has at least one physical size ranging from 1 to 100 nm to build material structures and structures with extraordinary properties (known as nanomaterials). With the ability to aid in visual representation, fate tracking, and controlling stem cells and the surrounding environment for tissue growth and repair, nanotechnology will undoubtedly revolutionize stem cell treatments for the treatment, identification, and treatment of human diseases. Nanomaterials (the smallest and lightest two-dimensional nanomaterial) have emerged as a constantly increasing star among nanoparticles because of their fascinating physical and chemical properties as well as the most promising uses in nanotechnology. Graphene (G), a particle acceleration layer of carbon atoms arranged in the double (2D) honeycomb lattice with distinctive physical, biochemical, and mechanical properties has gained worldwide acclaim because of its extraordinary physical and chemical characteristics. The potential of nanostructures and their highly speculative, graphene oxide (GO), to be biofunctionalized has impelled these nanostructures to the frontline and ignited intense interest in an extensive range of biotechnological applications, which include bioassays, biosensors, photothermal anti-carcinogenic therapy, and electronic power cell excitability. G and GO have recently time emerged as an intriguing nano-platform with important promise for biological devices and therapeutic interventions because of their distinct properties, which make graphene an ideal candidate for a wide range of medical applications such as skin engineering and the delivery of drugs. Interestingly, For example, graphene and nanocomposite sheets show some promise as a non-cytotoxic, transportable, and implanted environment for cell culture, permitting cancer cells to connect and proliferate. Graphene, in particular, has a tremendous potential to affect stem cell development.[116]

IV. CONCLUSIONS & FUTURE

Cancer is a complicated disease with numerous cell types and stages of development that drive normal biological pathways to recruit cells and resources for growth and survival. On the other hand, therapeutic options (drugs and chemicals) exhibit strong cytotoxicity, which not only targets cancer cells but also causes off-target cellular disarray and cell death, which are typically recognized as undesirable side effects and toxicities. Furthermore, many cancers develop resistance to treatment, necessitating the development of novel techniques based on drug-targeted carriers that deliver high concentrations of combinatorial drugs to specific targets. AuNPs will be more durable as target delivery systems if organ system loss is reduced and endothelium penetration is increased, as the former can result in a longer stay in circulation and the latter in higher targeting and drug accumulation. Multiple nanoparticles used together may be able to overcome the constraints of each nanoformulation. Researchers have demonstrated that they are effective vectorization systems for gene delivery and that they can be utilized to target biological processes involved in drug resistance and cancer cell survival. These nanoparticles can be mixed with other polymeric and/or metallic nanoparticles to be used in therapeutic treatments such as medication and thermal ablation because of their unique properties, AuNP preparations have a substantial impact on chemotherapeutic therapy in complex circumstances. The ability of nanomaterials to enter cells is a massive step forward in the usage of pharmacologic or environmentally photodynamic psychotherapy. In recent years, significant developments have been made in stem cell therapy, biomedical engineering, and genetic engineering. Because of its exceptional features like as excellent conductance, flexibility, and efficient molecule absorption, graphene can become the forthcoming generation of nanomaterials.

REFERENCES

[1]. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61(2): 69-90.
[2]. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Science 2011;102(7): 1247-1252.
[3]. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2007;2(12): 751-760.
[4]. Baptista PV. Cancer nanotechnology—prospects for cancer diagnostics and therapy. Current Cancer Therapy Reviews 2009;5(2): 80-88.
[5]. Conde J, Doria G, Baptista P. Noble Metal Nanoparticles Applications in Cancer. Journal of Drug Delivery 2012;2012(2012): 1-12.
[6]. Sanna A, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. International Journal of Nanomedicine 2014;9: 467-483.
[7]. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weiss- man IL, Wahl GM. Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Research 2006;66(19): 9339-9344.
[8]. Jordan CT, Guzman ML, Noble M. Mechanisms of Disease: Cancer Stem Cells. The New England Journal of Medicine 2006;355(12): 1253-1261.
[9]. Fernandes AR, Baptista PV. Nanotechnology for Cancer Diagnostics and Therapy – An Update on Novel Molecular Players. Current Cancer Therapy Reviews 2014;9(3): 1-9.
[10]. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews 2012;64: 24-36.
[11]. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharmaceutical Research 2010;27(12): 2569-2589.
[12]. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with the altered intracellular distribution of anticancer agents. Pharmacology & Therapeutics 2000;85(3): 217-229.
[13]. Conde J, de la Fuente JM, Baptista PV. Nanomaterials for reversion of multidrug resistance in cancer: new hope for an old idea? Frontiers and Pharmacology 2013;4(134): 1-5.
[14]. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews 2012;64: 206-212.
[15]. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Barnnerjee SK. Drug delivery systems: An updated review. International Journal of Pharmaceutical Investigation 2012;2(1): 2-11.
[16]. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release 2008;126(3): 187-204.
[17]. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005;1(3): 193-212.
[18]. Drbohlavova J, Chomoucka J, Adam V, Ryvolova M, Eckschlager T, Hubalek J, Kizek
[19]. R. Nanocarriers for Anticancer Drugs-New Trends in Nanomedicine. Current Drug Metabolism 2013;14(5): 547-564.
[20]. Baptista PV, Pereira E, Eaton P, Doria G, Miranda A, Gomes I, Quaresma P, Franco
[21]. R. Gold nanoparticles for the development of clinical diagnosis methods. Analytical Bioanalytical Chemistry 2008;391(3): 943-950.
[22]. Silva GA. Introduction to Nanotechnology and Its Applications to Medicine. Surgical Neurology 2004;61(3): 216-220.
[23]. Baptista PV. Could gold nanoprobes be an important tool in cancer diagnostics? Expert Reviews of Molecular Diagnostics 2012; 12(6): 541-543.
[24]. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine 2008;3(2): 133-149.
[25]. Ganesh T. Improved Biochemical Strategies for Targeted Delivery of Taxoids. Bioor- ganic & Medicinal Chemistry 2007;15(11): 3597-3623.
[26]. Hu CMJ, Zhang LF. Therapeutic Nanoparticles to Combat Cancer Drug Resistance. Current Drug Metabolism 2009;10(8): 836-841.
[27]. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Development of the polymer micelle carrier system for doxorubicin. Journal of Controlled Release 2001;74(1-3): 295-302.
[28]. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer 2005;5(3): 161-171.
[29]. Kim BY, Rutka JT, Chan WC. Nanomedicine. The New England Journal of Medicine 2010;363(25): 2434–2443.
[30]. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine challenge and perspectives. Angewandte Chemie International Edition England 2009;48(5): 872-897.
[31]. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery 2010;9(8): 615-627.
[32]. Bae KH, Chung HJ, Park TG. Nanomaterials for cancer therapy and imaging. Molecules and Cells 2011;31(4): 295-302.
[33]. Taylor A, Wilson KM, Murray P, Fernig DG, Levy R. Long-term tracking of cells using inorganic nanoparticles as contrast agents: are we there yet? Chemical Society Reviews 2012;41(7):2707-2717.
[34]. Villalonga-Barber C, Micha-Screttas M, Steele BR, Georgopoulos A, Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties.

Current Topics in Medicinal Chemistry 2008;8(14): 1294-1309.
[35]. Clift MJ, Stone V. Quantum dots: an insight and perspective of their biological interaction and how this relates to their relevance for clinical use. Theranostics 2012;2(7): 668-680.
[36]. Yamashita T, Yamashita K, Nabeshi H, Yoshikawa T, Yoshioka Y, Tsunoda S, Tsutsumi Y. Carbon nanomaterials: efficacy and safety for nanomedicine. Materials 2012;5(2): 350-363.
[37]. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls, and (pre-) clinical progress. Journal of Controlled Release 2012;161(2): 175-187.
[38]. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chemical Society Reviews 2012;41(7): 2780-2799.
[39]. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Advanced Drug Delivery Reviews 2008;60(11): 1307-1315.
[40]. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, Science, and Applications 2008;1: 17-32.
[41]. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. Journal of Controlled Release 2011;149(1): 65-71.
[42]. Pathak Y, Thassu D. Drug Delivery Nanoparticles Formulation and Characterization. Rijeka: PharmaceuTech Inc.; 2009. p1-393.
[43]. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics 2008;83(5): 761-769.
[44]. Davis ME, Chen ZG,Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery 2008;7(9): 771-782.
[45]. Dinarvand R, de Morais PC, D'Emanuele A. Nanoparticles for Targeted Delivery of Active Agents against Tumor Cells. Journal of Drug Delivery 2012; 2012(2012): 1-2.
[46]. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 2010;5(4): 523-528.
[47]. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303(5665): 1818-1822.
[48]. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Research 2000;60(15): 4251-4255.
[49]. Conde J, Rosa J, de la Fuente JM, Baptista PV. Gold-nano beacons for simultaneous gene-specific silencing and intracellular tracking of the silencing events. Biomaterials 2013;34(10): 2516-2523.
[50]. Gao H Yang Z, Zhang S, Cao S, Shen S, Pang Z, Jiang X. Ligand modified nanoparticle increases cell uptake, alters endocytosis, and elevates glioma distribution and internalization. Scientific Reports 2013;3(2534): 1-8.
[51]. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. PNAS 2007;104(39): 15549-15554.
[52]. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models. Cancer Research 2006;66(13): 6732-6740.
[53]. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine 2007;2(5): 681-693.
[54]. Figueiredo S, Cabral R, Luís D, Fernandes AR, Baptista PV. 2014. Integration of Gold nanoparticles and liposomes for combined anti-cancer drug delivery. In: Seifalian A. (ed.) Nanomedicine; University College London (UK); 2014. Chapter 3; available from http://www.onecentralpress.com/nanomedicine/#.
[55]. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chemical Society Reviews 2011;40(1): 44-56.
[56]. Kumar A, Boruah BM, Liang XJ. Gold nanoparticles: Promising nanomaterials for the diagnosis of cancer and HIV/AIDS. Journal of Nanomaterials 2011;2011(2011): 1-17.
[57]. Baptista PV, Doria G, Quaresma P, Cavadas M, Neves CS, Gomes I, Eaton P, Pereira E, Franco R. Nanoparticles in Molecular Diagnostics. In: Villaverde A. (ed.) Progress in Molecular Biology and Translational Science Elsevier Inc.; 2011. p427-488.
[58]. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters gold nanoparticles in targeted cancer drug delivery. Therapeutic Delivery 2012;3(4): 457-478.
[59]. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies, and toxicity. Chemical Society Reviews 2009;38(6): 1759-1782.
[60]. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics 2008;5(4): 505-515.
[61]. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angewandte Chemie International Edition England 2010;49(36): 6288-6308.
[62]. Mieszawska AJ, Mulder WJ, Fayad ZA, Cormode DP. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Molecular Pharmaceutics 2013;10(3): 831-47.

[63]. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as a biodegradable controlled drug delivery carrier. Polymers (Basel) 2011;3(3): 1377-1397.
[64]. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chemical Society Reviews 2012;41(7): 2545-2561.
[65]. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chemical Society Reviews 2013;42(3): 1147-1235.
[66]. Yazid H, Adnan R, Hamid SA, Farrukh MA. Synthesis and characterization of gold nanoparticles supported on zinc oxide via the deposition-precipitation method. Turkish Journal of Chemistry 2010;34: 639-650.
[67]. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. Journal of Pharmacy and Pharmacology 2008;60(8): 977-985.
[68]. Cabral R, Baptista PV. The chemistry and biology of gold nanoparticle-mediated photothermal therapy: promises and challenges. Nano LIFE 2013;3(3): 1330001.
[69]. Conde J, Ambrosone A, Sanz V, Hernandez Y, Marchesano V, Tian F, Child H, Berry CC, Ibarra MR, Baptista PV, Tortiglione C, de la Fuente JM. Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing. ACSNANO 2012;6(9): 8316-8324.
[70]. Murphy CJ, Gole AM, Hunyadi SE, Stone JW, Sisco PN, Alkilany A, Kinard BE, Han- kins P. Chemical sensing and imaging with metallic nanorods. Chemical Communications 2008;5: 544-557.
[71]. Huang CW, Hao YW, Nyagilo J, Dave DP, Xu LF, Sun XK. Porous Hollow Gold Nanoparticles for Cancer SERS Imaging. Journal of Nano Research 2010;10: 137-148.
[72]. Sirotkina MA, Elagin VV, Shirmanova MV, Bugrova ML, Snopova LB, Kamensky VA, Nadtochenko VA, Denisov NN, Zagaynova EV. OCT-guided laser hyperthermia with passively tumor-targeted gold nanoparticles. Journal of Biophotonics 2010;3(10-11): 718-727.
[73]. Cardinal J, Klune JR, Chory E, Jeyabalan G, Kanzius JS, Nalesnik M, Geller DA. Non-invasive Radiofrequency Ablation of Cancer Targeted by Gold Nanoparticles. Surgery 2008;144(2): 125-132.
[74]. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA. Intracellular gold nanoparticles enhance the non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. Journal of Nanobiotechnology 2008;6(2): 1-9.
[75]. Bhattacharya R, Mukherjee P. Biological properties of “naked” metal nanoparticles. Advanced Drug Delivery Reviews 2008;60(11): 1289-1306.
[76]. Wang J, Yao K, Wang C, Tang C, Jiang X. Synthesis and drug delivery of novel amphiphilic block copolymers containing hydrophobic dehydroabietic moiety. Journal of Materials Chemistry B 2013;1(17): 2324-2332.
[77]. Lim ZZJ, Li JEJ, Ng CT, Yung LYL, Bay BH. Gold nanoparticles in cancer therapy. Acta Pharmacologica Sinica 2011;32(8): 983-990.
[78]. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. Journal of Controlled Release 2010;148(1): 122-127.
[79]. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nature Reviews Cancer 2012;12(1): 39-50.
[80]. Hu CMJ, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery 2010;1(2): 323-334.
[81]. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology 2010;188(6): 759-768.
[82]. Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA. Tamoxifen-Poly(ethylene glycol)- Thiol Gold Nanoparticle Conjugates: Enhanced Potency and Selective Delivery for Breast Cancer Treatment. Bioconjugate Chemistry 2009;20(12): 2247-2253.
[83]. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. International Journal of Cancer 2007;120(12): 2527-2537.
[84]. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Advanced Drug Delivery Reviews 2010;62(11): 1064-1079.
[85]. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. PNAS 2006;103(16): 6315-6320.
[86]. Sapra P, Allen TM. Internalizing Antibodies is Necessary for Improved Therapeutic Efficacy of Antibody-targeted Liposomal Drugs. Cancer Research 2002;62(24): 7190-7194.
[87]. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. Journal of Controlled Release 2001;74(1-3): 95-113.
[88]. Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Molecular Pharmaceutics 2012;9(8): 2168-2179.
[89]. Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin MH, Wang HE. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorganic & Medicinal Chemistry Letters 2013;23(11): 3180-3185.
[90]. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R,

Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research 2002;62(24): 7350-7356.

[91]. Asadishad B, Vossoughi M, Alemzadeh I. Folate-Receptor-Targeted Delivery of Doxorubicin Using Polyethylene Glycol-Functionalized Gold Nanoparticles. Industrial & Engineering Chemistry Research 2010;49(4): 1958-1963.

[92]. Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Letters 2007;7(6): 1542-1550.

[93]. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. Journal of the American Chemical Society 2010;132(5): 1517-1519.

[94]. de la Fuente JM, Berry CC. Tat Peptide is an Efficient Molecule To Translocate Gold Nanoparticles into the Cell Nucleus. Bioconjugate Chemistry 2005;16(5): 1176-1180.

[95]. Lu W, Zhang G, Zhang R, Flores LG, 2nd, Huang Q, Gelovani JG, Li C. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Research 2010;70(8): 3177-3188.

[96]. Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JZ, Li C. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clinical Cancer Research 2009; 15(3): 876-886.

[97]. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proceedings of the National Academy of Sciences of the United States of America 2010;107(3): 1235-1240.

[98]. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, Stafford J, Olson T, Zhang JZ, Li C. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Molecular Cancer Therapeutics 2008;7(6): 1730-1739.

[99]. Park C, Youn H, Kim H, Noh T, Kook YH, Oh ET, Park HJ, Kim C. Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug. Journal of Materials Chemistry 2009;19(16): 2310-2315.

[100]. Han G, You CC, Kim BJ, Turingan RS, Forbes NS, Martin CT, Rotello VM. Light- Regulated Release of DNA and Its Delivery to Nuclei utilizing Photolabile Gold Nanoparticles. Angewandte Chemie International Edition England 2006;45(19): 3165-3169.

[101]. Hong R, Han G, Fernández JM, Kim BJ, Forbes NS, Rotello VM. Glutathione-Mediated Delivery and Release Using Monolayer Protected Nanoparticle Carriers. Journal of the American Chemical Society 2006;128(4): 1078-1079.

[102]. Mayer G, Heckel A. Biologically Active Molecules with a "Light Switch".Angewandte Chemie International Edition England 2006;45(30): 4900-4921.

[103]. McCoy CP, Rooney C, Edwards CR, Jones DS, Gorman SP. Light-Triggered Molecule-Scale Drug Dosing Devices. Journal of the American Chemical Society 2007;129(31): 9572-9573.

[104]. Li J, Gupta S, Li C. Research perspectives: gold nanoparticles in cancer theranostics. Quantitative Imaging in Medicine and Surgery. 2013;3(6): 284-291.

[105]. Agasti SS, Chompoosor A, You C-C, Ghosh P, Kim CK, Rotello VM. Photoregulated Release of Caged Anticancer Drugs from Gold Nanoparticles. Journal of the American Chemical Society 2009;131(16): 5728-5729.

[106]. You J, Zhang G, Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 2010;4(2): 1033-1041.

[107]. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, Rycenga M, Xie J, Kim C, Song KH, Schwartz AG, Wang LV, Xia Y. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nature Materials 2009;8: 935-939.

[108]. Gu YJ, Cheng J, Man CW, Wong WT, Cheng SH. Gold-doxorubicin nanoconjugates for overcoming multidrug resistance. Nanomedicine 2012;8(2): 204-211.

[109]. Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ. Gold Nanoparticles for the Improved Anticancer.

[110]. Drug Delivery of the Active Component of Oxaliplatin. Journal of the American Chemical Society 2010;132(13): 4678-4684.

[111]. Hunt KK, Vorburguer SA. Hurdles and Hopes for Cancer Therapy. Science 2002;297(5580): 415-416.

[112]. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature Reviews Drug Discovery 2009;8(2): 129-138.

[113]. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNA-nanoparticle conjugates. Journal of the American Chemical Society 2009;131(6): 2072-2073.

[114]. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312(5776): 1027-1030.

[115]. Han G, Martin CT, Rotello VM. Stability of Gold Nanoparticle-Bound DNA toward Biological, Physical, and Chemical Agents. Chemical Biology & Drug Design 2006;67(1): 78-82.

[116]. Han G, Chari NS, Verma A, Hong R, Martin CT, Rotello VM. Controlled Recovery of the Transcription of Nanoparticle-Bound DNA by Intracellular Concentrations of Glutathione.

Bioconjugate Chem. 2005;16(6): 1356-1359.
[117]. Lytton-Jean AK, Langer R, Anderson DG. Five years of siRNA delivery: spotlight on gold nanoparticles. Small 2011;7(14): 1932-1937.
[118]. Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors for Cancer Therapy. Journal of Nanomedicine and Nanotechnology 2013;4(6): 1-16.
[119]. Conde J, Tian F, Hernández Y, Bao C, Cui D, Janssen K-P, Ibarra MR, Baptista PV, Stoeger T, de la Fuente JM. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to an inflammatory response in lung cancer mouse models. Biomaterials 2013;34(31): 7744-7753.
[120]. Zhang W, Meng J, Ji Y, Li X, Kong H, Wu X, Xu H. Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system. Nanoscale 2011;3(9): 3923-3932.
[121]. Ryou SM, Park M, Kim JM, Jeon CO, Yun CH, Han SH, Kim SW, Lee Y, Kim S, Han MS, Bae J, Lee K. Inhibition of xenograft tumor growth in mice by gold nanoparticle- assisted delivery of short hairpin RNAs against Mcl-1L. Journal of Biotechnology 2011;156(2): 89-94.
[122]. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79(7): 1157-1164.
[123]. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochimica et Biophysica Acta 2010;1803(11): 1231-1243.
[124]. Yu Y, Sarkar FH, Majumdar APN. Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic regimens. Translational Oncology 2013;6(2):180-186.
[125]. Baguley BC. Multiple Drug Resistance Mechanisms in Cancer. Molecular Biotechnology 2010;46(3): 308-316.
[126]. Huls M, Russel FGM, Masereeuw R. The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ Regeneration. The Journal of Pharmacology and Experimental Therapeutics 2009;328(1): 3-9.
[127]. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. International Journal of Nanomedicine 2013;8(1): 899-908.
[128]. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-di- reacted Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer. Molecular Therapy-Nucleic Acids 2013;2(7): 1-11.
[129]. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, Duan Z. Inhibition of ABCB1 (MDR1) Expression by a siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. PLoS ONE 2010; 5(5): 1-12.
[130]. Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, Los M. Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer. Archivum Immunologiae et Therapiae Experimen- talis 2013;61(1): 43-58.
[131]. Amaravadi RK, Thompson CB. The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment. Clinical Cancer Research 2007;13(24): 7271-7279.
[132]. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for the treatment of multidrug-resistant cancer. Nanomedicine 2008;3(6): 761-776.
[133]. Kim D, Yu MK, Lee TS, Park JJ, Jeong YY, Jon S. Amphiphilic polymer-coated hybrid nanoparticles as CT/MRI dual contrast agents. Nanotechnology 2011;22(15): 1-7.
[134]. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, Schmid G, Brandau W, Jahnen-Dechent W. Size-dependent cytotoxicity of gold nanoparticles. Small 2007;3(11): 1941-1949.
[135]. Yildirimer L, Thanh NTK, Loizidou M, Seifalian AM. Toxicology and clinical potential of nanoparticles. Nano Today 2011;6(6): 585-607.
[136]. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chemistry 2004;15(4): 897-900.
[137]. Chen YS, Hung YC, Liau I, Huang GS. Assessment of the In Vivo Toxicity of Gold Nanoparticles. Nanoscale Research Letters 2009;4(8): 858-864.
[138]. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005;1(3): 325-327.
[139]. Tsoli M, Kuhn H, Brandau W, Esche H, Schmid G. Cellular uptake and toxicity of Au55 clusters. Small 2005;1(8-9): 841-844.
[140]. Ryan JA, Overton KW, Speight ME, Oldenburg CN, Loo L, Robarge W, Franzen S, Feldheim DL. Cellular uptake of gold nanoparticles passivated with BSA-SV40 large T antigen conjugates. Analytical Chemistry 2007;79(23): 9150-9159.
[141]. Nativo P, Prior IA, Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2008;2(8): 1639-1644.
[142]. Patra HK, Banerjee S, Chaudhuri U, Lahiri P, Dasgupta AK. Cell selective response to gold nanoparticles, Nanomedicine: Nanotechnology, Biology, and Medicine 2007;3(2): 111-119.
[143]. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Letters 2006;6(4): 662-668.
[144]. Jiang W, Kim BY, Rutka JT, Chan WC. The nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology 2008;3(3): 145-50.
[145]. Arnida, Malugin A, Ghandehari H. Cellular uptake

and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. Journal of Applied Toxicology 2010;30(3): 212-217.

[146]. Hauck TS, Ghazani AA, Chan WC. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 2008;4(1): 153-159.

[147]. Sabella S, Brunetti V, Vecchio G, Galeone A, Maiorano G, Cingolani R, Pompa P. Toxicity of citrate-capped AuNPs: an in vitro and in vivo assessment. Journal of Nanoparticle Research 2011;13(12): 6821-6835.

[148]. Pan Y, Leifert A, Ruau D, Neuss S, Bornemann J, Schmid G, Brandau W, Simon U, Jahnen-Dechent W. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small 2009;5(18): 2067-2076.

[149]. Li JJ, Hartono D, Ong CN, Bay BH, Yung LYL. Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials 2010;31(23): 5996-6003.

[150]. Li JJ, Zou L, Hartono D, Ong CN, Bay BH, Lanry Yung LY. Gold Nanoparticles In- duce Oxidative Damage in Lung Fibroblasts In Vitro. Advanced Materials 2008;20(1): 138-142.

[151]. Conde J, Larguinho M, Cordeiro A, Raposo LR, Costa PM, Santos S, Diniz MS, Fernandes AR, Baptista PV. Gold-nano beacons for gene therapy: evaluation of genotoxicity, cell toxicity, and proteome profiling analysis. Nanotoxicology 2014;8(5): 521-532.

[152]. Hackenberg S, Scherzed A, Kessler M, Hummel S, Technau A, Froelich K, Ginzkey C, Koehler C, Hagen R, Kleinsasser N. Silver nanoparticles: evaluation of DNA damage, toxicity and functional impairment in human mesenchymal stem cells. Toxicology Letters 2011;201(1): 27-33.

[153]. Asharani PV, Xinyi N, Hande MP, Valiyaveettil S. DNA damage and p53-mediated growth arrest in human cells treated with platinum nanoparticles. Nanomedicine 2010;5(1): 51-64.

[154]. El-Sayed I, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Letters 2006;239(1): 129-135.

[155]. Schaeublin NM, Braydich-Stolle LK, Schrand AM, Miller JM, Hutchison J, Schlager JJ, Hussain SM. The surface charge of gold nanoparticles mediates the mechanism of toxicity. Nanoscale 2011;3(2): 410-420.

[156]. Alkilany AM, Nagaria PK, Hexel CR, Shaw TJ, Murphy CJ, Wyatt MD. Cellular up- take and cytotoxicity of gold nanorods: molecular origin of cytotoxicity and surface effects. Small 2009;5(6): 701-708.

[157]. Cho WS, Cho M, Jeong J, Choi M, Cho HY, Han BS, Kim SH, Kim HO, Lim YT, Chung BH, Jeong J. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicology and Applied Pharmacology 2009;236(1): 16-24.

[158]. Chen YS, Hung YC, Liau I, Huang GS. Assessment of the In Vivo Toxicity of Gold Nanoparticles. Nanoscale Research Letters 2009;4(8): 858-864.

[159]. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008;29(12): 1912-1919.

[160]. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids and Surfaces B: Biointerfaces 2008;66(2): 274-280.

[161]. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schaffler M, Takenaka S, Moller W, Schmid G, Simon U, Kreyling WG. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics 2011;77(3): 407-416.

[162]. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chemical Society Reviews 2011;40(3): 1647-1671.

[163]. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 2008;3(5): 703-717.

[164]. Harper SL, Carriere JL, Miller JM, Hutchison JE, Maddux BL, Tanguay RL. Systematic evaluation of nanomaterial toxicity: utility of standardized materials and rapid assays. ACS Nano 2011;5(6): 4688-4697.

[165]. Pompa P, Vecchio G, Galeone A, Brunetti V, Sabella S, Maiorano G, Falqui A, Bertoni G, Cingolani R. In Vivo toxicity assessment of gold nanoparticles in Drosophila melanogaster. Nano Research 2011;4(4): 405-413.

[166]. Hu S, Zeng Y, Yang S, Qin H, Cai H, Wang J. Application of graphene-based nanotechnology in stem cells research. Journal of nanoscience and nanotechnology. 2015 Sep 1;15(9):6327-41.